1Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007,176:753-760.
2Dobler CC, Wong KK, Marks GB. Associations between statins and COPD :a systematic review. BMC Puhn Med,2009,9:32.
3Cazzola M, Ciaprini C, Page CP et at. Targeting systemic inflammation : novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opin Ther Targets, 2007, 11 : 1273-1286.
4Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Puimon Dis, 2012,7:571-576.
5Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med, 2005,172:987-993.
6Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol, 1998,18 : 1671-1678.
7Kim SE, Thanh Thny TT, Lee JH, et at. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophagcs exposed to cigarette smoke extract. Exp Mol Med,2009,41:277- 287.
8Nath N, Ciri S, Prasad R, et al. Potential targets of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol, 2004,172 : 1273-1286.
9Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitor, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coil Cardiol, 2006,47:2554- 2560.
10Walsh GM. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med, 2008,2 : 329-335.
8de Tortes JP,Cordoba-Lanus E,López-Aguilar C,et al.C-reactive protein levels and clinically important predictive outcomes in stable COPD patients[J].Eur Respir J,2006,27(5):902-907.
9Stolz D,Christ-Cmin M,Morgenthaler NG,et al.Copeptin,Creactive protein and procalcitonin as prognostic biomarkers in acute exacerbation of COPD[J].Chest,2007,131(4):1058-1067.
10Karaca L,Llkay E,Akbulut M,et al.Atorvastatin affects C-reactive protein levels in patients with coronary artery disease[J].Curr Med Res Opin,2003,19(3):187.
2Vargas M, Horcajada JP, Obach V, et al. Clinical consequences of infection in patients with acute stroke: is it prime time for further antibiotic trials? [J]. Stroke,2006,37(2) :461-465.
3Ersoz M, Ulusoy H, Oktar MA, et al. Urinary tract infection and bacteriurua in stroke patients :frequencies, pathogen microorganisms, and risk factors [ J ]. Am J Plays Med Rehabil, 2007,86 ( 9 ) : 734-741.
4Wartenberg KE,StoU A, Funk A, et al. Infection after acute ischemic stroke : risk factors, biomarkers, and outcome [ J ]. Stroke Res Treat, 2011,2011:830614.
5Ife~ika-Jones NL,Arun N ,Peng H,et al. The interaction of aspiration pneumonia with demographic and cerebrovascular disease riskfactors is predictive of discharge level of care in acute stroke patient [ J ]. Am ~ Ph3,s Med Rehabil,2012,91 (2) :141-147.
6Vogelgesang A, Becker K J, Dressel A. Immunological consequences of ischemic stroke [ J ]. Acta Neurol Scand ,2014,129 ( 1 ) : 1-12.
7Chamorro /~, Meisel A, Planas AM, et al. The immunology of acute stroke[J]. Nat Rev Neurol,2012,8(7) :401-410.
8Bao Y, Kim E, Bhosle S, et al. A role for spleen monocytes in post- ischemie brain inflammation and injury[ J ]. J Neuroinflammation, 2010,7:92-97.
9Meisel C, Schwab JM, Prass K, et al. Central nervous system injury- induced immune deficiency syndrome [ J ]. Nat Rev Neurosci, 2005, 6(10) :775-786.
10Iadecola C ,Anrather J. The immunology of stroke:from mechanisms to translation[J]. Nat Med,2011,17(7) :796-808.
